Robinhood Markets, Inc. Income Taxes Disclosure
| Year Ended December 31, | |||||||||||||||||
| (in millions) | 2023 | 2024 | 2025 | ||||||||||||||
| Domestic | $ | (534) | $ | 1,063 | $ | 2,086 | |||||||||||
| Foreign | 1 | 1 | 22 | ||||||||||||||
| Income (loss) before income taxes | $ | (533) | $ | 1,064 | $ | 2,108 | |||||||||||
| Year Ended December 31, | |||||||||||||||||
| (in millions) | 2023 | 2024 | 2025 | ||||||||||||||
| Current: | |||||||||||||||||
| Federal | $ | 5 | $ | 16 | $ | 22 | |||||||||||
| State | 3 | 6 | 18 | ||||||||||||||
| Foreign | — | — | 4 | ||||||||||||||
| Total current tax expense (benefit) | 8 | 22 | 44 | ||||||||||||||
| Deferred: | |||||||||||||||||
| Federal | — | (333) | 173 | ||||||||||||||
| State | — | (36) | 20 | ||||||||||||||
| Foreign | — | — | (12) | ||||||||||||||
| Total deferred tax expense (benefit) | — | (369) | 181 | ||||||||||||||
| Total provision for (benefit from) income taxes | $ | 8 | $ | (347) | $ | 225 | |||||||||||
| Year Ended December 31, 2025 | |||||||||||
Amount | Percent | ||||||||||
| Federal tax at statutory rate | $ | 443 | 21.0 | % | |||||||
State tax (benefit), net of federal benefit(1) | 34 | 1.6 | |||||||||
| Foreign tax effects | (12) | (0.6) | |||||||||
| Effect of cross-border tax laws | 1 | 0.1 | |||||||||
| Nontaxable or nondeductible items: | |||||||||||
| Share-based compensation | (184) | (8.7) | |||||||||
Others | 5 | 0.2 | |||||||||
Tax credits: | |||||||||||
| Research and development credits | (66) | (3.1) | |||||||||
Changes in unrecognized tax benefits | — | — | |||||||||
| Change in valuation allowance | 3 | 0.1 | |||||||||
| Other adjustments | 1 | 0.1 | |||||||||
Total provision for (benefit from) income taxes | $ | 225 | 10.7 | % | |||||||
| Year Ended December 31, | |||||||||||
| 2023 | 2024 | ||||||||||
| Federal tax at statutory rate | 21.0 | % | 21.0 | % | |||||||
State tax (benefit), net of federal benefit | (1.9) | 1.1 | |||||||||
| Share-based compensation | (29.7) | (3.5) | |||||||||
| Research and development credits | 5.6 | (4.8) | |||||||||
| Non-deductible regulatory settlements | (4.6) | (0.7) | |||||||||
| Other | 0.2 | 0.3 | |||||||||
| Change in valuation allowance | 8.0 | (46.0) | |||||||||
| Effective tax rate | (1.4) | % | (32.6) | % | |||||||
| Year Ended December 31, | ||||||||
| (in millions) | 2025 | |||||||
| U.S. federal | $ | 49 | ||||||
| U.S. state and local | 45 | |||||||
| Foreign | 1 | |||||||
| Total | $ | 95 | ||||||
| Year Ended December 31, | |||||||||||
(in millions) | 2024 | 2025 | |||||||||
| Deferred tax assets: | |||||||||||
| Tax credit carryforwards | $ | 174 | $ | 193 | |||||||
| Research and experimentation expenditure amortization | 248 | 122 | |||||||||
| Lease liabilities | 33 | 52 | |||||||||
| Net operating loss carryforwards | 29 | 40 | |||||||||
| Accruals and other liabilities | 16 | 29 | |||||||||
| Provision for credit losses | 16 | 28 | |||||||||
| Share-based compensation | 16 | 10 | |||||||||
| Other | 31 | 41 | |||||||||
| Total deferred tax assets | 563 | 515 | |||||||||
| Deferred tax liabilities: | |||||||||||
| Deferred customer match incentives | (74) | (153) | |||||||||
| Right of use assets | (24) | (43) | |||||||||
| Depreciation and amortization | (6) | (31) | |||||||||
| Other | — | (4) | |||||||||
| Total deferred tax liabilities | (104) | (231) | |||||||||
| Valuation allowance | (88) | (105) | |||||||||
| Net deferred tax assets | $ | 371 | $ | 179 | |||||||
| Year Ended December 31, | |||||||||||||||||
| (in millions) | 2023 | 2024 | 2025 | ||||||||||||||
| Balance at beginning of period | $ | 607 | $ | 574 | $ | 88 | |||||||||||
| Charged/(credited) to net income (loss) | (34) | (486) | 6 | ||||||||||||||
| Charges utilized/(write-offs) | 1 | — | — | ||||||||||||||
| Additions due to acquisition | — | — | 11 | ||||||||||||||
| Balance at end of period | $ | 574 | $ | 88 | $ | 105 | |||||||||||
| Year Ended December 31, | |||||||||||
(in millions) | 2024 | 2025 | |||||||||
| Unrecognized benefit - beginning of period | $ | 74 | $ | 98 | |||||||
| Gross increases - current year tax positions | 23 | 35 | |||||||||
| Gross increases - prior year tax positions | 1 | 1 | |||||||||
| Gross decreases - prior year tax positions | — | — | |||||||||
| Unrecognized benefit - end of period | $ | 98 | $ | 134 | |||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 18, 2026 | Showing above |
| 2024 | Feb 18, 2025 | |
| 2023 | Feb 27, 2024 | |
| 2022 | Feb 27, 2023 | |
| 2021 | Feb 24, 2022 | |
About Income Taxes Disclosures
The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.
Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.